PaulEdwardGossMDMBBCh, Ph.D.

Hematologic Oncology

Director of Breast Cancer Research, Massachusetts General Hospital; Co-Director, Breast Cancer Disease Program, Dana-Farber/Harvard Cancer Center (DF/HCC)

Join to view full profile

Are you Dr. Goss?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 22 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
55 Fruit St
Cox Building Ste 640
Boston, MA 02114
Phone+1 617-724-3118

Fax+1 617-724-3166

Summary

Dr. Paul Goss, MD is a hematologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Massachusetts General Hospital and is a Director of Breast Cancer Research at Breast Cancer Disease Program.

Education & Training

University of the WitwatersrandClass of 1978

Certifications & Licensure

MA State Medical License 2004 - 2021

Clinical Trials

Letrozole After Tamoxifen in Treating Women With Breast Cancer Start of enrollment: 1998 Aug 24
Completed
Phase 3
Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer Start of enrollment: 2003 Jun 06
Completed
Phase 3
Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer Start of enrollment: 2001 Aug 01
Completed
Not Applicable
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer Start of enrollment: 2004 Dec 03
Completed
Phase 3
Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer Start of enrollment: 2005 Jan 26
Completed
Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density Start of enrollment: 2000 Dec 05
Completed
Phase 2
Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer Start of enrollment: 2005 Oct 01
Unknown status
Phase 2
Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole Start of enrollment: 2006 Apr 01
Completed
Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial Start of enrollment: 2006 Apr 24
Completed
Phase 3
Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer Start of enrollment: 2007 Oct 01
Terminated
Phase 2
Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3 Start of enrollment: 2008 Jul 10
Completed
Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy Start of enrollment: 2004 Nov 23
Completed
Phase 3
Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17 Start of enrollment: 2006 Jun 01
Unknown status
Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy Start of enrollment: 2006 Aug 01
Completed
Join now to see all

Publications & Presentations

PubMed

Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial...
Judith-Anne W Chapman, Jane Bayani, Sandip SenGupta, John M S Bartlett, Tammy Piper
Journal of Clinical Oncology. 2024-08-20
Predicting the clinical outcomes and benefit from letrozole after 5 years of treatment with aromatase inhibitors for early breast cancer: analysis from CCTG MA.17R
Yapeng Li, Xueying Zheng, Dongsheng Tu, James N. Ingle, Paul E. Goss
Breast Cancer Research and Treatment. 2021-11-26
19 citations
Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes.
Sonali Jindal, Nathan D. Pennock, Duanchen Sun, Wesley Horton, Michelle K. Ozaki
Nature Communications. 2021-11-03

Press Mentions

Breast Cancer Symptoms: What Are the Early Signs You Should Look Out For?December 21st, 2022
New GCI Study on Gynecologic Cancers in Brazil Finds Most Patients Present with Advanced DiseaseJanuary 20th, 2021
Best Oncologists in BrisbaneJune 9th, 2019
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member